Dialysis industry news

Stories from the dialysis comunity across the globe.



DaVita Outperforms, Raises Guidance - Zacks.com PDF Print
Zacks.com
Segment wise, total revenue from the Dialysis and related Lab Services segment came in at $1.72 billion during the quarter, against $1.46 billion in the prior-year quarter. Operating income for the segment increased 38% year over year to $348 million

...

 
Hawthorn Improves Customer Experience Using iPads and MaaS360 - MarketWatch (press release) PDF Print

PHILADELPHIA, May 2, 2012 /PRNewswire via COMTEX/ -- Fiberlink®, the leader in software-as-a-service (SaaS) solutions for secure mobile device management (MDM) and mobile application management (MAM), today announced that Hawthorn Pharmaceuticals, Inc. deployed MaaS360 for the deployment of iPads and management of their mission-critical CRM application. Hawthorn chose the cloud-based solution to eliminate servers, forgo the need of internal staff constantly upgrading software and retain a system which can be rapidly distributed to field service employees. This approach gives Hawthorn a competitive advantage over other pharmaceutical companies and directly improves their customers' experience.

Hawthorn is a commercial-stage specialty pharmaceutical company that develops and markets prescription products in the therapeutic areas of respiratory, nephrology, dermatology, oncology, CNS and neurology. With an aggressive product development pipeline, including over 20 products in various stages of development and nine ANDA approvals in the last two years, Hawthorn's sales force was growing rapidly. Hawthorn purchased iPads to support the company's dynamic sales team with the iPoint CRM application. The native management utilities for iPads did not offer the level of device tracking, security and overall management that Hawthorn needed to conduct business in the highly regulated pharmaceuticals industry, so it turned to MaaS360 MDM for the answer.

"The fact that we could deploy MaaS360 so quickly and easily through the cloud was a significant advantage, giving our sales team a competitive edge and simplifying device management for our IT group," said Clay Hilton, director of Information Technology at Hawthorn. "MaaS360 enabled us to deploy iPads and apps to our entire sales force with zero risk of non-compliance. The MaaS360 cloud-based platform lets us concentrate directly on the strategic components that are critical for continued top line growth for the company. That's where the real ROI payoff sits."

MaaS360's web-based management console provides Hawthorn with complete control over the iPads and apps. Application visibility and reporting is critical for Hawthorn, as downtime can result in loss of pharmaceutical sample distribution data and risk of non-compliance with regulatory standards. With MaaS360's secure document sharing feature, Hawthorn automatically distributes and tracks acceptance of its compliance manual, alleviating any non-compliance concerns. Additionally, Hawthorn's ability to locate and wipe lost iPads from a central console remediates risk of exposing highly confidential client and product information. With MaaS360, Hawthorn iPads were enrolled in minutes, with Fiberlink's support team providing any needed guidance along the way.

"Hawthorn is a great example of how companies are leveraging iPads and mobile apps to keep their sales reps focused on being more responsive to their customers and generating revenue," said Christopher Clark, president at Fiberlink. "MaaS360 delivers critical MDM functionality and ease of use while providing benefits that only a cloud-based platform can offer."

About Fiberlink Fiberlink is the recognized leader in software-as-a-service (SaaS) solutions for secure enterprise mobile device and application management. Its cloud-based MaaS360 platform provides IT organizations with mobility intelligence and control over mobile devices, applications and content to enhance the mobile user experience and keep corporate data secure across smartphones, tablets and laptops. MaaS360 helps companies monitor the expanding suite of mobile operating systems, including Apple iOS, Android, BlackBerry and Windows Phone. Named by Network World as the Clear Choice Test winner for mobile device management solutions and honored with the 2012 Global Mobile Award for "Best Enterprise Mobile Service" at Mobile World Congress, MaaS360 is used to manage and secure more than one million endpoints globally. For more information, please visit http://www.maas360.com .

© 2012 MaaS360 and the MaaS360 logo are trademarks of Fiberlink Communications and may be registered in certain jurisdictions. All other brand names are trademarks of their respective partners.




        For Additional Information Contact:
        Fiberlink
        United States                    United Kingdom
        Joe Palladino or Lesley Sullivan Annie Barker or Alastair McCormack
        
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
           
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
 
        (781) 684-0770                   +44 (0)20 7878 3137
        



SOURCE Fiberlink

Copyright (C) 2012 PR Newswire. All rights reserved

...

 
Early Assessment by FDG-PET/CT of Patients with Advanced Renal Cell Carcinoma ... - 7thSpace Interactive (press release) PDF Print
7thSpace Interactive (press release)
PurposeWe reported previously that 18F-2-fluoro-2-deoxyglucose positron emission tomography/ computed tomography (FDG PET/CT) had potential for evaluating early response to treatment by tyrosine kinase inhibitors (TKIs) in advanced renal cell carcinoma

...

 
Organ donation gives back a life - Windsor Star PDF Print

As a recipient of a double kidney transplant on Oct. 25, 2011, and after marking Organ Donation Awareness Week in Canada, I want to give thanks for allowing me to get my life back.

I am now able to enjoy things without having to be hooked up to a machine for up to 3½ hours every other day.

The first set of thanks is to the wonderful donor who's wishes were carried out by his or her family. I would like to thank the wonderful people at London University Hospital, the senior surgeon and his associates.

The wonderful people in the transplant unit. The wonderful people in the nephrology followup clinic on the 10th floor. A special thanks to Miss Sue who was there to help resolve any problems I may have encountered.

PR's Hodsman and Turks for such sage advice. To Dr. Rehman and nurse Marianne, who really care, thank you. A thank you to Dr. A. Kadri who is doing followup in Windsor and helping me sort out a few glitches.

We all should remember when renewing our licences - organ donation should be in our minds all year not just one week. Remember precious gifts can do good here, not in heaven.

RICKY BROWN, Windsor

© Copyright (c) The Windsor Star

...

 
Vessix V2 Renal Denervation System for hypertension receives CE Mark approval - News-Medical.net PDF Print

Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received Conformite Europeenne (CE) Mark approval for its V2 Renal Denervation System™ for the treatment of hypertension. Renal denervation is a percutaneous, catheter-based therapy that uses RF energy to disrupt renal sympathetic nerves whose hyperactivity leads to uncontrolled high blood pressure

The CE Mark enables Vessix to market its patented V2 System throughout the European Union. The CE certification was issued to Vessix by its notified body, BSI Group, also known as the British Standards Institution.

"Vessix offers a unique approach to treating uncontrolled hypertension that provides excellent clinical results and is faster, easier to use and less painful for patients than any renal denervation system currently available in the market," said CEO Raymond W. Cohen. "After eight years optimizing RF balloon catheter and bipolar RF generator technologies, it is rewarding to see the V2 System working effectively in clinical practice to safely reduce patient blood pressures. As part of our commercialization strategy, Vessix has initiated a post-market approval surveillance study during which we plan to treat 120 patients at up to 20 international centers located across Western Europe."

Hypertension is the leading attributable cause of death worldwide. According to the American Heart Association, a 5 mm Hg (millimeters of mercury) reduction in systolic blood pressure results in a 14 percent decrease in stroke, a 9 percent decrease in heart disease and a 7 percent decrease in overall mortality. Renal denervation has shown in published clinical studies to be safe, durable and effective in reducing systolic blood pressure by approximately 20 percent.

Michael D. Gioffredi, Vessix's Chief Commercialization Officer said, "Renal denervation is rapidly becoming one of the most important medical device developments in decades and we believe that our unique design will set a new standard for the treatment.  In light of this regulatory clearance and the strong early clinical results from our multi-center European pilot study, we are moving forward with our commercialization plans in Europe and we look forward to sharing additional pre-clinical and human data at upcoming medical conferences in support of that launch."

...

 
<< Start < Prev 741 742 743 744 745 746 747 748 749 750 Next > End >>

Page 741 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.